Zoetis Inc. (ZTS) Receives Consensus Recommendation of “Buy” from Analysts
Zoetis Inc. (NYSE:ZTS) has been assigned an average rating of “Buy” from the fifteen brokerages that are covering the company. Two research analysts have rated the stock with a sell recommendation, three have assigned a hold recommendation, eight have given a buy recommendation and two have issued a strong buy recommendation on the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $55.46.
ZTS has been the topic of a number of recent research reports. Jefferies Group reiterated a “buy” rating and issued a $60.00 price objective on shares of Zoetis in a report on Tuesday, August 23rd. Zacks Investment Research downgraded shares of Zoetis from a “buy” rating to a “hold” rating in a report on Thursday, October 6th. Guggenheim reiterated a “positive” rating and issued a $60.00 price objective on shares of Zoetis in a report on Monday, August 22nd. Stifel Nicolaus reiterated a “buy” rating and issued a $58.00 price objective on shares of Zoetis in a report on Wednesday. Finally, Barclays PLC lifted their price objective on shares of Zoetis from $45.00 to $49.00 and gave the company an “equal weight” rating in a report on Thursday, August 4th.
Zoetis (NYSE:ZTS) traded up 0.75% during trading on Wednesday, reaching $51.34. 2,099,782 shares of the company traded hands. The company has a market cap of $25.42 billion, a PE ratio of 39.98 and a beta of 1.01. Zoetis has a 12 month low of $38.26 and a 12 month high of $53.14. The company’s 50-day moving average is $51.24 and its 200 day moving average is $48.92.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/12/zoetis-inc-zts-receives-consensus-recommendation-of-buy-from-analysts.html
Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Wednesday, August 3rd. The company reported $0.49 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.44 by $0.05. Zoetis had a net margin of 13.15% and a return on equity of 77.58%. The company had revenue of $1.20 billion for the quarter, compared to the consensus estimate of $1.17 billion. During the same period last year, the company earned $0.43 earnings per share. The firm’s revenue was up 2.8% compared to the same quarter last year. On average, analysts anticipate that Zoetis will post $1.91 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 1st. Stockholders of record on Thursday, November 3rd will be given a $0.095 dividend. The ex-dividend date of this dividend is Tuesday, November 1st. This represents a $0.38 dividend on an annualized basis and a dividend yield of 0.75%. Zoetis’s payout ratio is presently 29.69%.
In other Zoetis news, Director Michael B. Mccallister bought 2,000 shares of Zoetis stock in a transaction dated Tuesday, September 6th. The stock was bought at an average price of $51.34 per share, with a total value of $102,680.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Andrew Fenton sold 13,870 shares of the business’s stock in a transaction dated Friday, September 2nd. The shares were sold at an average price of $51.25, for a total transaction of $710,837.50. Following the completion of the sale, the insider now directly owns 17,719 shares of the company’s stock, valued at approximately $908,098.75. The disclosure for this sale can be found here. 0.05% of the stock is currently owned by insiders.
Several large investors have recently made changes to their positions in the stock. NEXT Financial Group Inc increased its position in Zoetis by 9.5% in the second quarter. NEXT Financial Group Inc now owns 2,136 shares of the company’s stock worth $101,000 after buying an additional 186 shares during the period. Kelly Lawrence W & Associates Inc. CA increased its position in Zoetis by 113.4% in the second quarter. Kelly Lawrence W & Associates Inc. CA now owns 2,446 shares of the company’s stock worth $116,000 after buying an additional 1,300 shares during the period. Northwestern Mutual Wealth Management Co. increased its position in Zoetis by 22.8% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 2,566 shares of the company’s stock worth $121,000 after buying an additional 476 shares during the period. NN Investment Partners Holdings N.V. bought a new position in Zoetis during the first quarter worth approximately $118,000. Finally, Glenmede Trust Co. NA increased its position in Zoetis by 4.4% in the second quarter. Glenmede Trust Co. NA now owns 2,950 shares of the company’s stock worth $139,000 after buying an additional 124 shares during the period. 93.12% of the stock is owned by institutional investors.
Zoetis Company Profile
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a diversified business, marketing products across over eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock), and dogs, cats and horses (collectively, companion animals), and within over five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.